A randomized study to evaluate tolerance, pharmacokinetics, and short term efficacy of seven doses of the short –acting formulation of ICI 182,780 in women prior to surgery for primary breast cancer.

Study identifier:9238HQ/0002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized study to evaluate tolerance, pharmacokinetics, and short term efficacy of seven doses of the short –acting formulation of ICI 182,780 in women prior to surgery for primary breast cancer.

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria